Effect of food on the pharmacokinetics of zoliflodacin granules for oral suspension: Phase I <scp>open‐label</scp> randomized cross‐over study in healthy subjects
Alison Luckey(Global Antibiotic Research & Development Partnership), Jean‐Yves Gillon(Drugs for Neglected Diseases Initiative), Sophie Delhomme(Drugs for Neglected Diseases Initiative), John P. O’Donnell(Entasis Therapeutics (United States)), Seamus O’Brien(Pfizer (United States)), Esther Bettiol(Global Antibiotic Research & Development Partnership), Emilie Alirol(Global Antibiotic Research & Development Partnership), John P. Mueller(Innoviva (United States))
Cited by 6
Related Papers
Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study
|Journal of Antimicrobial Chemotherapy|2019|123
Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial
|The Lancet Infectious Diseases|2024|98
The Pharmacokinetics/Pharmacodynamic Relationship of Durlobactam in Combination With Sulbactam in In Vitro and In Vivo Infection Model Systems Versus <i>Acinetobacter baumannii-calcoaceticus</i> Complex
|Clinical Infectious Diseases|2023|32
Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for Phase IIa and Phase III evaluation
|European Journal of Clinical Pharmacology|2024|28